Bozhinova S, Markova S, Tsvetkov Ts, Penkov V, Ivanova I
Akush Ginekol (Sofiia). 2002;41(6):17-22.
Magnesium sulphate (MgSO4) is with a proved effectiveness in cases of praeclampsia/eclampsia, but its use as a tocolytic is discussed in the last few years. That is why we had for an object to study its effect as a tocolytic in cases of abortions and premature labours. The study is prospective and if is made in I-st obstetric clinic of High Medical School--Pleven. Treatment with Cormagnesin was carried out to pregnant women for suppressing the uterine activity. Cormagnesin 200 (1 amp-10 ml) contains 1000 mg MgSO4, and Cormagnesin 400 (1 amp-10 ml) contains 2000 mg MgSO4. The medicine was administered in dosage of 4 or 5 g for 30 min, and after that if there were any uterine contractions the infusion was carried on with additional 5 g MgSO4 for 6 to 12 h. The total dosage was from 4 to 60 g MgSO4. The authors reported on very good effect in cases with pains and increased uterine tone--18 (36.73%), as well as in cases with pains and irregular uterine contractions 5 (10.21%), while the treatment was without any effect in cases with uterine contractions on 15-20 min, increased uterine tone, bleeding and Pelvic score 1-3 points in spite of high dosages of MgSO4 and longer duration of treatment. The authors made the conclusion, that the subjective complaints should not be accepted as an indication for administration of MgSO4, and MgSO4 should be administered in cases with increased uterine tone and irregular uterine contractions. Every genital bleeding and suspicion for placental abruption should be defined more precisely, because lately diagnosed placental abruption and unjustified expectation for suppression of uterine activity by MgSO4, may lead to increase of perinatal morbidity and mortality. In spite of the controversial data about MgSO4 as a tocolytic, its administration is justified and necessary.
硫酸镁(MgSO4)在子痫前期/子痫病例中已被证明有效,但近年来其作为宫缩抑制剂的应用存在争议。这就是为什么我们旨在研究其在流产和早产病例中作为宫缩抑制剂的效果。该研究是前瞻性的,在普列文高等医学院第一产科诊所进行。使用可镁信(Cormagnesin)对孕妇进行治疗以抑制子宫活动。可镁信200(1安瓿 - 10毫升)含有1000毫克硫酸镁,可镁信400(1安瓿 - 10毫升)含有2000毫克硫酸镁。药物以4或5克的剂量给药30分钟,之后如果有任何子宫收缩,则继续输注额外的5克硫酸镁6至12小时。总剂量为4至60克硫酸镁。作者报告称,在有疼痛和子宫张力增加的病例中有非常好的效果——18例(36.73%),以及在有疼痛和不规律子宫收缩的病例中有5例(10.21%),而在子宫收缩间隔为每分钟15 - 20次、子宫张力增加、出血且骨盆评分1 - 3分的病例中,尽管使用了高剂量的硫酸镁且治疗时间较长,但治疗没有任何效果。作者得出结论,主观症状不应被视为使用硫酸镁的指征,硫酸镁应在子宫张力增加和不规律子宫收缩的病例中使用。每例生殖器出血和胎盘早剥的怀疑都应更精确地界定,因为近期诊断的胎盘早剥以及对硫酸镁抑制子宫活动的不合理期望,可能会导致围产期发病率和死亡率增加。尽管关于硫酸镁作为宫缩抑制剂的数据存在争议,但其给药是合理且必要的。